Get Professional Valuation and Credit Risk Reports of Any Company in the World
New AI-Powered Free Company Valuation tool for any company in the world. Upload a PDF financial statement to receive an instant report with customizable forecasts, credit score, default probability and key financial metrics. Try Now for Free →
Get Professional Valuation and Credit Risk Reports of Any Company in the World
- Get an AI-powered company valuation or credit risk report in just 2 minutes
- Get reports of any company in the world with a financial statement in any language
- Upload a PDF financial statement to receive an instant report with customizable forecasts, credit score, default probability and key financial metrics
Ascendis Pharma Endocrinology Division A/S — Credit Rating and Financial Key Figures
CVR number: 32323537
Tuborg Boulevard 12, 2900 Hellerup
Income statement (mEUR)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 157.40 | 122.88 | 140.82 | ||
| Costs of manufacturing | -40.00 | -73.63 | |||
| Gross profit | 157.40 | 82.88 | 67.19 | ||
| Costs of management | -39.67 | -6.76 | |||
| Other operating expenses | - 110.89 | - 110.79 | |||
| EBIT | -86.98 | - 190.16 | -38.31 | -67.67 | -50.36 |
| Other financial income | 12.04 | 92.61 | |||
| Other financial expenses | -65.70 | -83.33 | |||
| Pre-tax profit | -98.89 | - 205.63 | -60.90 | - 121.33 | -41.07 |
| Income taxes | 0.21 | 2.27 | |||
| Net earnings | -98.89 | - 205.63 | -60.90 | - 121.12 | -38.81 |
Assets (mEUR)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 0.07 | 0.05 | |||
| Tangible assets total | 0.07 | 0.05 | |||
| Investments total | 43.22 | 55.41 | 102.21 | ||
| Non-current loans receivable | 22.50 | 73.76 | |||
| Long term receivables total | 22.50 | 73.76 | |||
| Inventories total | |||||
| Current trade debtors | 0.53 | 0.86 | |||
| Prepayments and accrued income | 1.46 | 1.41 | |||
| Current other receivables | 0.69 | 2.05 | |||
| Short term receivables total | 2.68 | 4.33 | |||
| Cash and bank deposits | 0.04 | 0.00 | |||
| Cash and cash equivalents | 0.04 | 0.00 | |||
| Balance sheet total (assets) | 43.22 | 55.41 | 102.21 | 25.30 | 78.14 |
Equity and liabilities (mEUR)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | - 509.20 | - 714.82 | - 775.73 | 0.13 | 0.13 |
| Retained earnings | 98.89 | 205.63 | 60.90 | - 775.86 | - 896.98 |
| Profit of the financial year | -98.89 | - 205.63 | -60.90 | - 121.12 | -38.81 |
| Shareholders equity total | - 509.20 | - 714.82 | - 775.73 | - 896.84 | - 935.65 |
| Non-current loans from credit institutions | 142.01 | 110.68 | |||
| Non-current owed to group member | 759.35 | 874.48 | |||
| Non-current accruals and deferred income | 5.00 | ||||
| Non-current liabilities total | 906.36 | 985.16 | |||
| Current loans from credit institutions | 14.83 | 15.69 | |||
| Current owed to participating | 11.03 | ||||
| Other non-interest bearing current liabilities | 0.01 | 0.01 | |||
| Accruals and deferred income | 0.94 | 1.89 | |||
| Current liabilities total | 15.78 | 28.63 | |||
| Balance sheet total (liabilities) | - 509.20 | - 714.82 | - 775.73 | 25.30 | 78.14 |
CreditReports API
- Company information
- Financial data
- Credit risk data
- All 400,000+ Danish companies
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.